#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage II Sjogren's syndrome Neoplasm Follicle centre lymphoma follicular grade I II – III refractory B precursor type acute leukaemia Lymphoma Haemophilia A with anti factor VIII Pleural mesothelioma malignant Neuroendocrine tumour of the lung Acute on chronic liver failure Non-Hodgkin's lymphoma refractory Paget's disease of the vulva Bulbospinal muscular atrophy congenital Head and neck cancer Progressive familial intrahepatic cholestasis More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage III – Trials in Disease Skin angiosarcoma – Life with Disease Brain stem glioma – Basic Information Langerhans’ cell histiocytosis SAPHO syndrome Mantle cell lymphoma stage III – Basic Information Sarcoidosis – Treatment Acquired haemophilia – Diagnostics X-linked lymphoproliferative syndrome – Diagnostics Wolfram syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Syn321 Alxn2220 Gsk6097608 Highly Refined Fish Oil Allopurinol Ro7589655 LIGUFALIMAB Capmatinib Sabatolimab Elebsiran Clonazepam Elacestrant HYDROGEN PEROXIDE Albiglutide JX10 Dexmedetomidine GSKVX000000017986 Amphotericine B, Liposome Bbp-398 Levoleucovorin Disodium More therapies…

    Learn about Your Condition

    Malignant melanoma stage IV Epileptic encephalopathy Small intestine leiomyosarcoma Mantle cell lymphoma Hypersensitivity Liver disorder Pulmonary venous thrombosis Ocular myasthenia Testicular germ cell cancer Rett syndrome Clinically isolated syndrome Transferrin decreased Cardiac amyloidosis Electrocorticogram Blood disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Ente Ecclesiastico Ospedale Generale Regionale Miulli…

Ente Ecclesiastico Ospedale Generale Regionale Miulli

Strada Provinciale No 127, Acquaviva Santeramo Km 4 100, Acquaviva Delle Fonti, 70021, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Bempedoic Acid
    • Obicetrapib
    Czechia Germany Italy The Netherlands Poland Slovakia +1

  • A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

    Recruiting

    3 1
    Investigated Diseases:
    • Pulmonary hypertension
    Investigated Drugs:
    • Levosimendan
    Austria Bulgaria Czechia France Germany Hungary +3

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Colchicine and Aspirin for Improving Heart Health in Adults with Type 2 Diabetes Without Previous Heart Events

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Carbasalate Calcium
    • Colchicine
    Denmark Finland France Greece Italy Portugal

  • Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Cisplatin
    Italy

  • Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Bladder cancer
    France Germany Italy Spain

  • Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Deucrictibant
    Austria Bulgaria France Germany Hungary Ireland +5

  • Study on Pre-Surgery Treatment for Locally Advanced Cholangiocarcinoma Using Durvalumab, Tremelimumab, Cisplatin, and Gemcitabine

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    Italy

  • Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Olaparib
    Italy
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!